AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update endorsed by the National Heart, Lung, and Blood Institute

J Am Coll Cardiol. 2006 May 16;47(10):2130-9. doi: 10.1016/j.jacc.2006.04.026.

Authors

AHA; ACC; National Heart, Lung, and Blood Institute; Sidney C Smith Jr, Jerilyn Allen, Steven N Blair, Robert O Bonow, Lawrence M Brass, Gregg C Fonarow, Scott M Grundy, Loren Hiratzka, Daniel Jones, Harlan M Krumholz, Lori Mosca, Thomas Pearson, Marc A Pfeffer, Kathryn A Taubert

PMID: 16697342
DOI: 10.1016/j.jacc.2006.04.026

No abstract available

Publication types

Practice Guideline

MeSH terms

Adrenergic beta-Antagonists / therapeutic use
Angiotensin II Type 1 Receptor Blockers / therapeutic use
Angiotensin-Converting Enzyme Inhibitors / therapeutic use
Atherosclerosis / complications
Atherosclerosis / therapy
Cardiovascular Agents / therapeutic use*
Coronary Artery Disease / complications
Coronary Artery Disease / therapy*
Diabetes Mellitus / therapy
Dyslipidemias / therapy
Health Behavior
Hematologic Agents / therapeutic use
Humans
Hypertension / complications
Hypertension / therapy
Hypolipidemic Agents / therapeutic use
Influenza Vaccines
Mineralocorticoid Receptor Antagonists / therapeutic use
Motor Activity
Obesity / therapy
Smoking Cessation

Substances

Adrenergic beta-Antagonists
Angiotensin II Type 1 Receptor Blockers
Angiotensin-Converting Enzyme Inhibitors
Cardiovascular Agents
Hematologic Agents
Hypolipidemic Agents
Influenza Vaccines
Mineralocorticoid Receptor Antagonists